Scholar Rock Holding Corporation
SRRK
Classifica tra le azioni
#3430
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Prezzo delle azioni
$41.58
Ultima sincronizzazione: 2026-10-20
Capitalizzazione di mercato
$5.06B
Variazione (1 giorno)
3.34%
Variazione (1 anno)
47.62%
Paese
US
Scambia Scholar Rock Holding Corporation (SRRK)
Categoria
Healthcare
Ricavi di Scholar Rock Holding Corporation (SRRK)
Ricavi nel Jun 2026 TTM: 0.00
Secondo gli ultimi rapporti finanziari di Scholar Rock Holding Corporation, i ricavi attuali dell'azienda (TTM) sono pari a 0.00. Nel 2023, l'azienda ha registrato ricavi di 0.00 una diminuzione rispetto a i ricavi dell'anno 2022, che erano pari a $33.19M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Scholar Rock Holding Corporation da 2016 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | $33.19M | 76.41% |
| 2021 | $18.82M | 22.16% |
| 2020 | $15.40M | -24.83% |
| 2019 | $20.49M | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | -100.00% |
| 2016 | $379.00K | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| - | - |
CH
|
|
| $6.02B | - |
NL
|
